Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC
Lillian L. Siu(University Health Network), Jérôme Fayette(Université Claude Bernard Lyon 1), Lisle M. Nabell(Memorial Sloan Kettering Cancer Center), Sophie Wildsmith(AstraZeneca (United Kingdom)), Hisham Mehanna(University Hospitals Birmingham NHS Foundation Trust), Jean‐Pierre Delord, Éva Remenár(National Institute of Oncology), Nuria Kotecki(Centre Oscar Lambret), Dan P. Zandberg(University of Pittsburgh Medical Center), Nabil F. Saba(Emory University), Ricard Mesı́a(Institut d'Investigació Biomédica de Bellvitge), Irene Braña(Vall d'Hebron Institute of Oncology), Neal Ready(Duke University), J. Armstrong(AstraZeneca (United States)), Amaury Daste(Centre Hospitalier Universitaire de Bordeaux), Anthony Jarkowski(AstraZeneca (United States)), Jürgen Krauß(National Center for Tumor Diseases), Jill Gilbert(Cancer Clinic), Giovanni Melillo(AstraZeneca (Brazil)), Caroline Even(Institut Gustave Roussy), Marcelo Bonomi
Cited by 315
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Dose Escalation Methods in Phase I Cancer Clinical Trials
|JNCI Journal of the National Cancer Institute|2009|856
Head and neck cancer
|The Lancet|2021|829